Insomnia therapeutics, including benzodiazepines, nonbenzodiazepines, orexin antagonists, and melatonin antagonists, address a prevalent sleep disorder affecting 10-30% of the global population, with chronic insomnia at 5-10%. The market is driven by rising anxiety and depression, with a 25% increase in cases post-COVID-19, and high prevalence in women and the elderly (20-40%).
Orexin antagonists like suvorexant and daridorexant, with low dependency, reduce sleep onset by 30 minutes and improve maintenance by 60%. The aging population (1 billion over 60 in 2020, projected to reach 2.1 billion by 2050), health education, and 60% reimbursement coverage in OECD countries boost demand. The global insomnia therapeutics market is estimated at USD 1.5-3.0 billion in 2025, with a CAGR of 3%-7% through 2030.
This product will be delivered within 1-3 business days.
Orexin antagonists like suvorexant and daridorexant, with low dependency, reduce sleep onset by 30 minutes and improve maintenance by 60%. The aging population (1 billion over 60 in 2020, projected to reach 2.1 billion by 2050), health education, and 60% reimbursement coverage in OECD countries boost demand. The global insomnia therapeutics market is estimated at USD 1.5-3.0 billion in 2025, with a CAGR of 3%-7% through 2030.
Regional Market Trends
- North America: The U.S. leads with high insomnia diagnoses and orexin antagonist adoption, while Canada focuses on sleep clinics.
- Europe: Germany, France, and the UK drive growth with robust mental health services.
- Asia Pacific: China and India see rising demand due to urban stress, with Japan emphasizing novel therapies.
- Rest of the World: Brazil expands access to generics, while the Middle East addresses sleep health.
Application Analysis
- Prescription: Expected growth of 3.5%-7.5%, driven by chronic insomnia. Trends focus on low-dependency drugs.
- Over-the-Counter (OTC): Projected growth of 3.0%-7.0%, linked to mild cases. Advances emphasize natural supplements.
Type Analysis
- Benzodiazepines: Expected growth of 2.5%-6.5%, used for short-term relief. Trends focus on limited use due to dependency.
- Nonbenzodiazepines: Projected growth of 3.2%-7.2%, favored for safety. Advances emphasize short-acting agents.
- Antidepressants: Anticipated growth of 2.8%-6.8%, suited for comorbid insomnia. Trends highlight low-dose options.
- Orexin Antagonists: Expected growth of 4.0%-8.0%, valued for low dependency. Developments prioritize long-term efficacy.
- Melatonin Antagonists: Expected growth of 3.5%-7.5%, used for sleep regulation. Trends focus on OTC formulations.
- Others: Expected growth of 2.5%-6.5%, covering novel therapies. Trends highlight non-drug options.
Key Market Players
- Merck: Offers suvorexant for insomnia.
- Sanofi: Provides nonbenzodiazepine therapies.
- Takeda Pharmaceutical: Develops sleep disorder treatments.
- Pfizer: Supplies antidepressants for insomnia.
- Idorsia: Specializes in daridorexant formulations.
Porter’s Five Forces Analysis
- Threat of New Entrants: Moderate, due to high R&D costs, but OTC supplements lower barriers.
- Threat of Substitutes: High, with non-drug therapies like CBT-I competing, but drugs are primary for severe cases.
- Bargaining Power of Buyers: High, as generics and OTC options increase price competition.
- Bargaining Power of Suppliers: Low, with multiple API providers.
- Competitive Rivalry: High, with players competing on efficacy and safety.
Market Opportunities and Challenges
Opportunities:
- Addressing insomnia, affecting 10-30% of the population.
- Leveraging orexin antagonists, improving sleep maintenance by 60%.
- Managing anxiety and depression, with 25% case increase post-COVID-19.
- Supporting an aging population, with 20-40% insomnia prevalence.
- Utilizing 60% reimbursement coverage in OECD countries.
- Expanding health education, increasing diagnosis rates to 50%.
Challenges:
- High costs of novel therapies like orexin antagonists.
- Regulatory scrutiny on dependency risks.
- Competition from non-drug therapies like CBT-I.
- Patient adherence issues with long-term treatments.
- Limited access in low-income regions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Historical and Forecast Insomnia Therapeutics Market in North America (2020-2030)
Chapter 9 Historical and Forecast Insomnia Therapeutics Market in South America (2020-2030)
Chapter 10 Historical and Forecast Insomnia Therapeutics Market in Asia & Pacific (2020-2030)
Chapter 11 Historical and Forecast Insomnia Therapeutics Market in Europe (2020-2030)
Chapter 12 Historical and Forecast Insomnia Therapeutics Market in MEA (2020-2030)
Chapter 13 Summary For Global Insomnia Therapeutics Market (2020-2025)
Chapter 14 Global Insomnia Therapeutics Market Forecast (2025-2030)
Chapter 15 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Merck
- Sanofi
- Takeda Pharmaceutical
- Pfizer
- Vanda Pharmaceuticals
- Teva Pharmaceutical
- Viatris
- Sumitomo Pharma
- Ebb Therapeutics
- Idorsia
- Eisa
